Literature DB >> 33817753

Analysis of 14 endocannabinoids and endocannabinoid congeners in human plasma using column switching high-performance atmospheric pressure chemical ionization liquid chromatography-mass spectrometry.

Cristina Sempio1, Jelena Klawitter1, Matthew Jackson1, Francesca Freni1,2, Ryan Shillingburg1, Kent Hutchison3,4, L Cinnamon Bidwell3, Uwe Christians1, Jost Klawitter5,6,7.   

Abstract

The endocannabinoid system (ECS) is a complex cell-signaling system. To address the growing need of analytics capturing endocannabinoid levels to investigate the ECS, we developed and validated an assay for the quantitative analysis of 14 endocannabinoids and congeners. A simple extraction using protein precipitation with acetonitrile followed by online-trapping high-performance liquid chromatography-tandem mass spectrometry (LC/LC-MS/MS) was used to monitor the levels of 14 endocannabinoids in plasma. The assay was validated and intra-run and inter-run accuracies and imprecisions as well as matrix effects, recoveries, and sample stabilities were determined. As a proof of concept, a subset of study samples after naturalistic administration of Cannabis flower and concentrate was analyzed. With the exception of N-oleoyl dopamine and oleamide, all endocannabinoids fulfilled the predefined acceptance criteria. Reproducible recoveries and no significant matrix effects were observed. Sample stability was an issue. Analysis of the proof-of-concept study samples revealed a significantly (p = 0.006) higher concentration of docosatetraenoyl ethanolamide in concentrate users (300 ± 13 pg/mL) compared to flower users (252 ± 11 pg/mL). A robust, sensitive high-throughput assay for the quantitation of 14 endocannabinoids and congeners was successfully validated. Our study showed that it is mandatory to (A) appropriately stabilize samples and (B) separate and separately quantify 1-AG and 2-AG; otherwise, study results are unreliable. The analysis of study samples from Cannabis flower users versus Cannabis concentrate users revealed higher levels of docosatetraenoyl ethanolamide and anandamide (n.s.) in high THC concentrate users in accordance with the existing literature, supporting the validity of the assay measurements. Graphical abstract.

Entities:  

Keywords:  2-Arachidonoylglycerol; Anandamide; Cannabinoids; Docosatetraenoyl ethanolamide; Endocannabinoid System; Endocannabinoids

Year:  2021        PMID: 33817753     DOI: 10.1007/s00216-021-03280-0

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  47 in total

Review 1.  GPR55: Current knowledge and future perspectives of a purported "Type-3" cannabinoid receptor.

Authors:  Alessio Moriconi; Ilaria Cerbara; Mauro Maccarrone; Alessandra Topai
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  Fatty acids, endocannabinoids and inflammation.

Authors:  Renger Witkamp
Journal:  Eur J Pharmacol       Date:  2015-08-29       Impact factor: 4.432

Review 4.  The Endocannabinoid System and its Modulation by Phytocannabinoids.

Authors:  Vincenzo Di Marzo; Fabiana Piscitelli
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

5.  Endocannabinoids and their implications for epilepsy.

Authors:  Bradley E Alger
Journal:  Epilepsy Curr       Date:  2004 Sep-Oct       Impact factor: 7.500

Review 6.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

Review 7.  The role of the endocannabinoid system in pain.

Authors:  Stephen G Woodhams; Devi Rani Sagar; James J Burston; Victoria Chapman
Journal:  Handb Exp Pharmacol       Date:  2015

Review 8.  The cannabinoid system and pain.

Authors:  Stephen G Woodhams; Victoria Chapman; David P Finn; Andrea G Hohmann; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

Review 9.  From surface to nuclear receptors: the endocannabinoid family extends its assets.

Authors:  M Pistis; M Melis
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 10.  Anandamide receptors.

Authors:  Vincenzo Di Marzo; L De Petrocellis; F Fezza; A Ligresti; T Bisogno
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2002 Feb-Mar       Impact factor: 4.006

View more
  3 in total

1.  Measuring the Content of Endocannabinoid-Like Compounds in Biological Fluids: A Critical Overview of Sample Preparation Methodologies.

Authors:  Heather B Bradshaw; Clare T Johnson
Journal:  Methods Mol Biol       Date:  2023

2.  Endocannabinoid System in Polycystic Kidney Disease.

Authors:  Jost Klawitter; Cristina Sempio; Matthew J Jackson; Peter H Smith; Katharina Hopp; Michel Chonchol; Berenice Y Gitomer; Uwe Christians; Jelena Klawitter
Journal:  Am J Nephrol       Date:  2022-03-09       Impact factor: 4.605

Review 3.  The Role of Cannabinoids in Bone Metabolism: A New Perspective for Bone Disorders.

Authors:  Federica Saponaro; Rebecca Ferrisi; Francesca Gado; Beatrice Polini; Alessandro Saba; Clementina Manera; Grazia Chiellini
Journal:  Int J Mol Sci       Date:  2021-11-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.